Envision Inc. Files 2024 10-K

TL;DR

Envision Inc. filed its 2024 10-K, covering FY24. All systems go.

AI Summary

Envision Inc. filed its 10-K for the fiscal year ending March 31, 2024, reporting on its operations in surgical and medical instruments. The company, formerly known as Electros Cope Inc., is based in Boulder, Colorado. The filing covers the period from April 1, 2023, to March 31, 2024, and includes financial data for the fiscal years 2023 and 2024.

Why It Matters

This filing provides a comprehensive overview of Envision Inc.'s financial health and business operations for the past fiscal year, which is crucial for investors and stakeholders to assess the company's performance and future prospects.

Risk Assessment

Risk Level: low — The provided text is a standard 10-K filing header and does not contain specific financial performance details or forward-looking statements that would indicate a high risk.

Key Numbers

• 2024-03-31 — Fiscal Year End (Reporting period for the 10-K)
• 2023-04-01 — Fiscal Year Start (Beginning of the reporting period)
• 2022-04-01 — Prior Fiscal Year Start (Beginning of the previous reporting period)
• 2023-03-31 — Prior Fiscal Year End (End of the previous reporting period)

Key Players & Entities

• ENCISION INC (company) — Filer
• ELECTROSCOPE INC (company) — Former Company Name
• 0000930775 (company) — Central Index Key
• 3841 (company) — Standard Industrial Classification Code
• CO (company) — State of Incorporation
• 841162056 (company) — IRS Number
• 3034442600 (dollar_amount) — Business Phone Number
• 001-11789 (company) — SEC File Number
• 241117460 (company) — Film Number

FAQ

Key Financial Figures

• $0.46 — d on the average bid and asked price of $0.46 per share of the issuer's common stock
• $100 billion — providers and represents approximately $100 billion in annual medical devices and supplies
• $500 million — oscopic hand instruments, approximately $500 million in sales annually are derived from inst

Filing Documents

• ecia_10k.htm (10-K) — 885KB
• ex23x1.htm (EX-23.1) — 4KB
• ex31x1.htm (EX-31.1) — 7KB
• ex31x2.htm (EX-31.2) — 7KB
• ex32x1.htm (EX-32.1) — 7KB
• image_001.jpg (GRAPHIC) — 4KB
• image_002.gif (GRAPHIC) — 3KB
• 0001079973-24-001051.txt ( ) — 5361KB
• ecia-20240331.xsd (EX-101.SCH) — 35KB
• ecia-20240331_cal.xml (EX-101.CAL) — 54KB
• ecia-20240331_def.xml (EX-101.DEF) — 139KB
• ecia-20240331_lab.xml (EX-101.LAB) — 338KB
• ecia-20240331_pre.xml (EX-101.PRE) — 291KB
• ecia_10k_htm.xml (XML) — 850KB

The 2024 Proxy Statement will be filed within 120 days after the end of the fiscal year ended March 31, 2024

Part III. The 2024 Proxy Statement will be filed within 120 days after the end of the fiscal year ended March 31, 2024. Table of Contents Item 1. Business 2 Item 1A. Risk Factors 9 Item 1B. Unresolved Staff Comments 13 Item 1C. Cybersecurity 13 Item 2. Properties 13 Item 3. Legal Proceedings 13 Item 4. Mine Safety Disclosures 13 PART II Item 5. Market for Registrant's Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities 14 Item 6. [ Reserved ] 14 Item 7. Management's Discussion and Analysis of Financial Condition and Results of Operations 14 Item 7A. Quantitative and Qualitative Disclosures About Market Risk 18 Item 8. Financial Statements and Supplementary Data 18 Item 9. Changes in and Disagreements with Accountants on Accounting and Financial Disclosure 35 Item 9A. Controls and Procedures 36 Item 9B. Other Information 36 PART III Item 10. Directors, Executive Officers and Corporate Governance 37 Item 11. Executive Compensation 37 Item 12. Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters 37 Item 13. Certain Relationships and Related Transactions, and Director Independence 37 Item 14. Principal Accounting Fees and Services 37 PART IV Item 15. Exhibits, Financial Statement Schedules 37 Item 16. Form 10-K Summary 37 Forward-Looking contained in this Annual Report on Form 10-K include forward looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and involve substantial risks and uncertainties that may cause actual results to differ materially from those indicated by the forward looking statements. All forward looking statements in this Annual Report on Form 10-K, including statements about our strategies, expectations about new and existing products, market demand, acceptance of new and existing products, technologies and opportunities, market size and gr

Business

Business Highlights Proprietary, Patented Technology We have developed and launched patented AEM Surgical Instruments and Monitors that enhance patient safety and patient outcomes in laparoscopic surgical procedures. We have been issued 16 unexpired patents relating to AEM technology from the United States Patent and Trademark Office, each encompassing multiple claims, and which have between one and seventeen years remaining. We also have patents relating to AEM technology issued in Europe, Japan, Canada and Australia. Technology Solves a Well Documented Risk in Minimally Invasive Surgery MIS offers significant benefits for patients by reducing trauma, hospital stays, recovery times and medical costs. However, these benefits have not been achieved without the emergence of new risks. The risk of unintended tissue damage from stray electrosurgical energy has been well documented. Such injuries can be especially troubling given that often these injuries are out of the field of view, can go unrecognized at the time of surgery, and can lead to a cascade of adverse events, including death. Our patented AEM technology eliminates the risk of stray electrosurgical burns in MIS while providing surgeons with the tissue effects they desire. 2 Product Line has been Developed and Launched Our AEM Surgical Instruments and Monitors have been engineered to provide a seamless transition for surgeons switching from conventional laparoscopic instruments. AEM technology has been integrated into instruments that have the same look, feel and functionality as conventional instruments that surgeons have been using for years. The AEM product line encompasses a full range of instrument sizes, types and styles favored by surgeons. While always quality-centric, we added a new level of customer-centricity with increased marketing focus on our reposable AEM EndoShield 2 Burn Protection System ("EndoShield 2"). The EndoShield 2 can be used for a number of surgical procedures without

View Full Filing

View this 10-K filing on SEC EDGAR